Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose IMD-1041 in a nasal allergen challenge model
2007-000190-28Phase 2Completed
- Sponsor
- Institute of Medicinal Molecular Design, Inc.
- Start
- Feb 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in allergic rhinitis (AR) comparing IMD-1041 with Placebo (2 arms). Primary endpoints: Safety, efficacy and potential therapeutic benefit of IKKB inhibition in man by oral dosing of IMD-1041, Effects of IMD-1041 on key pathological parameters and 1 more. Started Feb 2011; status: completed.
02
Drugs
IMD-1041
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on 2007-000190-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000190-28.